{"filing":{"accession_number":"0001493152-26-025335","cik":"0001904286","ticker":"MIRA","company_name":"MIRA PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226025335/form8-k.htm"},"events":[{"id":8826,"run_id":7748,"accession_number":"0001493152-26-025335","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The filing discloses entry into Amendment No. 1 to an Exclusive License Agreement with MIRALOGX LLC on May 21, 2026 (Item 1.01). The amendment materially expands the Company's exclusive licensed territory for Ketamir-2 from the US, Canada, and Mexico to all countries with patent rights, and expands the licensed patent portfolio internationally across multiple jurisdictions. While the core economic terms remain unchanged, the territorial and patent scope expansion represents a material modification to the Company's rights and development strategy for a key asset, supporting continued global development and commercialization of Ketamir-2.","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":2032,"accession_number":"0001493152-26-025335","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses entry into Amendment No. 1 to an Exclusive License Agreement with MIRALOGX LLC on May 21, 2026 (Item 1.01). The amendment materially expands the Company's exclusive licensed territory for Ketamir-2 from the US, Canada, and Mexico to all countries with patent rights, and expands the licensed patent portfolio internationally across multiple jurisdictions. While the core economic terms remain unchanged, the territorial and patent scope expansion represents a material modification to the Company's rights and development strategy for a key asset, supporting continued global development and commercialization of Ketamir-2.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:37:29.376196+00:00","company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","filing_date":"2026-05-27"}]}